Public Health and Rare Diseases: Oxymoron No More
ESSAY — Volume 13 — January 14, 2016
Rodolfo Valdez, PhD; Lijing Ouyang, PhD; Julie Bolen, PhD
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.
The mission of public health has been succinctly stated as “the fulfillment of society’s interest in assuring conditions in which people can be healthy” (1). Public and private institutions charged with this mission monitor population health and respond when threats arise. These may be sudden health crises (eg, infectious outbreaks), persistent health problems (eg, chronic diseases), or buildups of environmental risk factors (eg, pollution). Public health practitioners use a combination of disciplines that include basic science, clinical research, epidemiology, statistics, behavioral research, health care services, economics, and policy to identify the primary or secondary causes of health threats and then systematically prevent, mitigate, or suppress these causes in entire populations. This approach has been tremendously successful against infectious diseases and has had notable successes against injuries, accidents, and major chronic diseases (2,3). The purpose of this essay is to highlight the case of a group of nearly 7,000 rare (low-prevalence) diseases, mostly of genetic or congenital origin, for which the applicability of the public health approach, primary prevention in particular, seems limited. We argue that a wider application of this approach could greatly benefit the patients affected by these diseases and their relatives. We start by presenting the challenges of implementing this approach for rare diseases, then we present the need for such an approach and a few notable examples of its successful application to these diseases. Finally, we provide a structured list of public health activities that are key to the management of rare diseases in populations.
A rare disease is a condition that affects fewer than 200,000 people in the United States or no more than 1 of every 2,000 people in Europe (4). Examples of rare diseases are life-threatening and physically or mentally disabling conditions such as Huntington disease, spina bifida, fragile X syndrome, Guillain-Barré syndrome, Crohn disease, cystic fibrosis, and Duchenne muscular dystrophy. Possibly the main reason for the limited applicability of the public health approach to rare diseases is that patients are few and scattered across populations. But another reason is that approaches based on identifying and removing risk factors are generally not well-suited for diseases whose primary risk factors are innate or congenital and therefore irremovable.
Additionally, many rare diseases have a long list of characteristics that present serious challenges for public health practitioners (5). Among rare diseases it is common to find that 1) diagnoses are difficult and delayed; 2) case definitions for surveillance are usually lacking; 3) International Classification of Diseases (ICD) codes for record keeping are poorly defined or not assigned; 4) underlying molecular or physiologic mechanisms are unknown; 5) specialized and coordinated medical care is in short supply, and treatments can be complex; 6) standards of care for treatment and rehabilitation are not evidence-based because health research is necessarily done at small scale; 7) longitudinal data collections are scarce; 8) the development of new medications and treatments can be fragmented and slow; 9) screening strategies lack efficiency; and 10) scope and capacity of most registries and databases are limited. Our knowledge of most rare diseases is so insufficient that they are also known as orphan diseases because of their failure to attract the interest of researchers, medical specialists, drug makers, and policy makers (5).
Despite the challenges, we have compelling reasons to apply a public health approach to rare diseases: they collectively affect about 25 million people in the United States, about 30 million in Europe, and about 400 million worldwide (4); most rare diseases begin in childhood and can have devastating health consequences, including premature death. They can severely affect the lives of caregivers; their economic impact is often substantial for patients, their families, and society in general (6,7). Although rare diseases are a common cause of neurological and intellectual disabilities and many have no cure, some can be prevented or controlled and the lifespan of patients can be extended into adulthood with opportune medical interventions. A few large-scale public health approaches that have been successfully used on rare diseases offer concrete examples in favor of this view. For decades, screening of newborns has been used to ameliorate or prevent adverse metabolic and developmental consequences among children born with treatable rare conditions in the United States and other countries (8,9). Mandatory folic acid fortification of enriched cereal grain products has contributed to the reduction of neural tube defects, including spina bifida, in populations (10,11). The life expectancy of cystic fibrosis patients has increased from under 10 to over 40 years of age in the past few decades as advances in medical care reach larger segments of their population (12). The prevalence of a severe genetic disease, Tay-Sachs, has been drastically reduced among the Ashkenazi Jewish population through population screening and strategies such as prenatal diagnosis for carrier couples and marriage avoidance between carriers (13,14).
Important support for a public health approach to rare diseases has also come through the services rendered by patient organizations to their members and through policy efforts that include the passage of legislation such as the Orphan Drug Act and the Rare Diseases Act, which have encouraged research and drug development. Evidence suggests that efforts of this type have empowered patients with rare diseases and their organizations as they seek and obtain wider social recognition, more participation in research, and better health care (15,16).
Given the difficulty of the challenges involved, public health approaches may not seem suitable for rare diseases when the primary measures of success relate to the prevention of large numbers of cases or the avoidance of premature deaths. A closer look, however, may confirm that individuals affected by disabling, life-threatening, and largely unpreventable diseases benefit enormously from a comprehensive public health approach to control conditions associated with these diseases in their populations. Although we want to keep focus on primary prevention whenever possible, an alternative measure of success on rare diseases could be, for example, slowing down the clinical progression while reducing their adverse impact on the lives of affected individuals, their relatives, and their caregivers. A host of activities that can be undertaken to control rare diseases fall within the domain of public health. The Box lists goals for a comprehensive public health approach to rare diseases. Generally, these activities have been proposed for single rare diseases, but much more can be gained from a public health standpoint by focusing these actions and measuring their impact on groups of rare diseases with common characteristics and risk factors.
The authors declare no conflict of interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Corresponding Author: Rodolfo Valdez, PhD, MSc, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E-88, Atlanta, GA 30333. Telephone: 404-498-0072. Email: email@example.com.
Author Affiliations: Lijing Ouyang, Julie Bolen, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Institute of Medicine. The future of public health. IOM Publication no. 88-02. National Academy Press: Washington (DC); 1988.
- Centers for Disease Control and Prevention (CDC). Ten great public health achievements — United States, 2001–2010. MMWR Morb Mortal Wkly Rep 2011;60(19):619–23. PubMed
- Norheim OF, Jha P, Admasu K, Godal T, Hum RJ, Kruk ME, et al. Avoiding 40% of the premature deaths in each country, 2010–30: review of national mortality trends to help quantify the UN sustainable development goal for health. Lancet 2015;385(9964):239–52. CrossRef PubMed
- de Vrueh R, Baekelandt ERF, de Haan JMH. Priority medicines for Europe and the world: “a public health approach to innovation.” WHO Background Paper 6.19. Rare Diseases; 2013. http://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf. Accessed December 16, 2015.
- Institute of Medicine (US). Rare diseases and orphan products: accelerating research and development 2010. Washington (DC): National Academies Press; 2010.
- Rofail D, Maguire L, Kissner M, Colligs A, Abetz-Webb L. A review of the social, psychological, and economic burdens experienced by people with spina bifida and their caregivers. Neurol Ther 2013;2(1–2):1–12.CrossRef PubMed
- Ouyang L, Grosse SD, Riley C, Bolen J, Bishop E, Raspa M, Bailey DB Jr. A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability. Res Dev Disabil 2014;35(7):1518-27. PubMed
- Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics 2006;117(3):923–9.CrossRef PubMed
- Therrell BL, Adams J. Newborn screening in North America. J Inherit Metab Dis 2007;30(4):447–65.CrossRef PubMed
- Wolff T, Witkop CT, Miller T, Syed SB; US Preventive Services Task Force. Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2009;150(9):632–9. CrossRef PubMed
- Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, et al. Updated estimates of neural tube defects prevented by mandatory folic acid fortification — United States, 1995–2011. MMWR Morb Mortal Wkly Rep 2015;64(1):1–5. PubMed
- MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 2014;161(4):233–41. CrossRef PubMed
- Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. The International TSD Data Collection Network. Tay-Sachs disease — carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. JAMA 1993;270(19):2307–15. CrossRef PubMed
- Lew RM, Burnett L, Proos AL, Barlow-Stewart K, Delatycki MB, Bankier A, et al. Ashkenazi Jewish population screening for Tay-Sachs disease: the international and Australian experience. J Paediatr Child Health 2015;51(3):271–9. CrossRef PubMed
- Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet 2008;371(9629):2048–51. CrossRef PubMed
- Dunkle M, Pines W, Saltonstall PL. Advocacy groups and their role in rare diseases research. In: Posada de la Paz M, Groft SC, editors. Rare Diseases Epidemiology. Adv Exp Med Biol 2010;686:515–25. New York (NY): Springer Science; 2010.